UPMC Hillman Cancer Center

Da Yang, MD, PhD

Da Yang
Assistant Professor of Pharmaceutical Sciences


Contact Information

Contact Information

308 Pavilion
Pittsburgh, PA 15213

Phone: 412-383-5145
Email: dyang@pitt.edu

Research Keywords

Research Keywords

Drug resistance; genomics; epigenetics; cancer therapeutics; biomarkers; personalized cancer medicine

Research Summary

Research Summary

The research of Dr. Yang’s laboratory focuses on using integrated genomic and functional studies to identify mechanisms of resistance to cancer therapeutics, and to develop novel approaches and biomarkers to enable personalized cancer medicine. Currently, ongoing work involves: 1) mechanistic studies of resistance to cancer therapeutics, especially targeted therapy for pathways with the most prevalent genomic alterations in human solid tumors; and 2) characterization of genetic and epigenetic alterations of non protein-coding components (ncRNAs) of the genome, such as miRNA and lncRNA genes in solid tumors. His approaches have proved successful in several instances, including the identification of miR-506 as a tumor suppressor that inhibits epithelial-to-mesenchymal transition (EMT) and cell cycle pathways, and the discovery of BRCA2 gene mutations that lead to genome instability and cisplatin response in ovarian cancer.

Selected Publications

Selected Publications

  • Cancer Genome Atlas Network (including Yang D). Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015 Jun 25;372(26):2481-98. PubMed Link
  • Cancer Genome Atlas Network (including Yang D). Genomic classification of cutaneous melanoma. Cell. 2015 Jun 18;161(7):1681-96. PubMed Link
  • Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, Chen K, Mezzanzanica D, Xue F, Sood AK, Zhang W. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst. 2015 May 20;107(7). PubMed Link
  • Chen K, Yang D, Li X, Sun B, Song F, Cao W, Brat DJ, Gao Z, Li H, Liang H, Zhao Y, Zheng H, Li M, Buckner J, Patterson SD, Ye X, Reinhard C, Bhathena A, Joshi D, Mischel PS, Croce CM, Wang YM, Raghavakaimal S, Li H, Lu X, Pan Y, Chang H, Ba S, Luo L, Cavenee WK, Zhang W, Hao X. Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1107-12. PubMed Link
  • Song F, Yang D, Liu B, Guo Y, Zheng H, Li L, Wang T, Yu J, Zhao Y, Niu R, Liang H, Winkler H, Zhang W, Hao X, Chen K. Integrated microRNA network analyses identify a poor-prognosis subtype of gastric cancer characterized by the miR-200 family. Clin Cancer Res. 2014 Feb 15;20(4):878-89. PubMed Link
  • Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, Cogdell D, Nykter M, Broaddus R, Rodriguez-Aguayo C, Lopez-Berestein G, Liu J, Shmulevich I, Sood AK, Chen K, Zhang W. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013 Feb 11;23(2):186-99. PubMed Link
  • Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A, Gonzalez-Villasana V, Huang L, Zand B, Moreno-Smith M, Mangala LS, Taylor M, Dalton HJ, Sehgal V, Wen Y, Kang Y, Baggerly KA, Lee JS, Ram PT, Ravoori MK, Kundra V, Zhang X, Ali-Fehmi R, Gonzalez-Angulo AM, Massion PP, Calin GA, Lopez-Berestein G, Zhang W, Sood AK. Tumour angiogenesis regulation by the miR-200 family. Nat Commun. 2013;4:2427. PubMed Link
  • Yang J, Yang D, Sun Y, Sun B, Wang G, Trent JC, Araujo DM, Chen K, Zhang W. Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer. 2011 Nov 1;117(21):4925-38. PubMed Link
  • Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang W. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011 Oct 12;306(14):1557-65. PubMed Link
  • Gu Y, Yang D, Zou J, Ma W, Wu R, Zhao W, Zhang Y, Xiao H, Gong X, Zhang M, Zhu J, Guo Z. Systematic interpretation of comutated genes in large-scale cancer mutation profiles. Mol Cancer Ther. 2010 Aug;9(8):2186-95. PubMed Link

See all pubs (Pubmed)

Department Website

Lab Website









Last modified: 11/18/15